• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    CRO Market Insights

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services

    Helsinn Establishes New R&D Hub in the U.S.

    CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Qosina

    IDT Biologika

    Aphena Pharma Solutions

    Biosynth Carbosynth

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Qosina

    IDT Biologika

    Aphena Pharma Solutions

    Biosynth Carbosynth

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Preclinical Outsourcing

    Strategic Intentions

    Gauging the fallout from the Covance-Sanofi pact

    Related CONTENT
    • Frontage Laboratories Appoints Executive Director, Regional Head of Sales, West
    • Frontida BioPharm Launches Expansion Efforts
    • Recro Gainesville Expands Mfg. Capabilities
    • Diverse Products And Technologies Delivered
    • PPD Expands Vaccine Development Lab
    Steve Snyder11.10.10

    In a year that has seen a perplexing continuation of the slowdown in customer demand for preclinical outsourcing, Covance recently announced a new strategic deal with Sanofi-Aventis. We'll explore the impact of this partnership on Covance, Sanofi, and the preclinical outsourcing industry at large.


    The Deal


    As widely reported in the financial press, Covance will become a primary provider of research services for Sanofi. It is important to note that the services provided by Covance will include clinical services and chemistry services, but this column will only focus on the impact of the deal on preclinical outsourcing. Covance will purchase Sanofi operations in France and the UK. Employees at these facilities will become Covance employees. The deal for Covance is valued as high as $2.2 billion over

    10 years.


    What Does the Deal Mean for Covance?


    Once the deal is closed, receiving between $1.2 and $2.2 billion in guaranteed revenue over the next 10 years will help Covance temper the cyclic nature of customer demand for preclinical outsourcing. The Sanofi deal follows Covance's first asset transfer deal with Lilly, which was valued at $1.6 billion for Covance. Covance has since been able to commercialize the former Lilly site in Greenfield, IN to serve other clients in addition to fulfilling its Lilly service obligations. The Sanofi deal further differentiates Covance in the industry as having the ability to close deals of this magnitude. Locking in long-term guaranteed revenue would seemingly enable more strategic decision-making and help minimize market driven reactive decisions.


    By acquiring research operations in France and the UK, Covance significantly improves its European presence. These facilities will join the existing Covance portfolio of European preclinical facilities in Harrogate, UK and Muenster, Germany. As Covance realized with the Lilly deal, one of the real benefits may be the acquisition of experienced Sanofi researchers. If managed effectively, the overall gain of research experience can only help to diversify Covance's existing scientific expertise. Like some other preclinical CROs, Covance has been adept at moving employees among its sites to address operational needs. Having additional experienced staff can only extend this flexibility. As I have stated in the past, facilities don't conduct research; people conduct research.


    What Does the Deal Mean for Sanofi?


    At a time when pharmaceutical companies are looking to cut costs, the Covance deal allows Sanofi to reduce some of its fixed overhead expenses. Transferring two research facilities and their employees to Covance helps to achieve this goal. As long as Covance performs to Sanofi's expectations, Sanofi could also benefit by reducing external service agreements and the subsequent costs associated with maintaining those relationships.


    What Are the Challenges for Covance?


    How will former Sanofi employees transition to CRO work? Working for a CRO is much different that working for a pharmaceutical company. The pace is faster and the expectations for customer service are much greater. Frankly, some individuals just aren't cut out for the CRO work environment. If Covance decides to maintain Sanofi's site management teams, these teams will need to deliver the level of research quality and service that Covance and Sanofi will expect. Again, this is easier said than done, as CRO work requires a different mindset than what is needed in pharmaceutical research operations.


    Will Covance commercialize the newly acquired Sanofi research operations? By "commercialize," I mean, will Covance look to provide services from the former Sanofi facilities for clients other than Sanofi? While Covance has proven successful in commercializing the former Lilly facility in Greenfield, IN, it has been suggested that some potential clients will not place work there due to lingering confidentiality concerns arising from Covance's partnership withLilly. Furthermore, any clients that Covance may seek to attract to the former Sanofi facilities will need to be convinced that the employee concerns that were expressed above have been addressed.


    Will Covance have too much global capacity? The preclinical outsourcing industry in 2010 is still experiencing the low customer demand that first started to decline in 2008. While it is reported that client requests for bids remain high, there has been no definitive evidence that we will see a marked improvement in demand for the immediate future. Over this timeframe, the preclinical CRO industry has cut costs through layoffs and, in some cases, reducing capacity. Despite its previous strategic deals, Covance has not been immune to these market forces. Some financial analysts have suggested that Covance may announce a cost-cutting initiative but no such news has been announced at press time. While the Sanofi sites will provide Covance with a greater presence in Europe, their management team will be challenged to balance workload across their operations. Despite best intentions and talk of teamwork, multi-site preclinical CROs can end up competing with their sister sites because individual site revenue generation is often a measure of management effectiveness. Finally, despite additional governmental scrutiny, animal liberation activities are still a significant concern for European preclinical CROs and their clients.


    Will the Sanofi facilities conduct regulated drug development activities? With the Lilly deal, Covance made a strategic decision not to conduct GLP toxicology work at the Greenfield facility, a site focused on late discovery/early development non-GLP activities. This decision enabled Covance to commercialize this facility faster, since they did not have to build the infrastructure to support GLP work. If it is determined that the Sanofi operations acquired by Covance will conduct regulated work, Covance will need to make sure that regulatory compliance is consistent with its expectations and with those of its clients. The decision could be significant in that there seems to be growing scrutiny of CRO operations by the FDA. As reported in my October 2010 Contract Pharma column, "Regulatory Shock-waves," the FDA is seeking to prevent sponsors from commenting on or editing contributor reports from CROs until the contributor report has been finalized. If this enforcement action is maintained, sponsors may become even more selective in choosing preclinical outsourcing partners; they may be inclined to work with CRO scientists who are more familiar to them. This is pure speculation but if true, it may be more difficult for any new CRO operation to be embraced by the client community.


    Is Covance's preclinical business too large to be managed effectively? There really is no standard to determine the "appropriate" size of a preclinical operation. Covance has been harmonizing multi-site preclinical operations since the mid-1990s. Their management team seemingly understands that harmonization and operational optimization is an ongoing process. Covance scientists could be challenged to balance additional harmonization efforts while maintaining an appropriate focus on ongoing client studies. Covance seems to have an appropriate management structure to direct a growing preclinical operation. Still, especially after the explosive growth in industry capacity in 2007 and 2008, some CROs have been challenged to maintain quality and acceptable service. Maintaining quality and customer service is a challenge that all CROs face on a daily basis. It is worth considering then whether this daily challenge becomes greater as a management team is tasked with additional operational and strategic responsibilities. Established work processes may not be as effective as the size of a preclinical operation expands. The problem is that a CRO may not realize that a work process is no longer effective until quality issues arise. Some clients shy away from large CROs because they are concerned that they won't receive the attention and level of customer service that they expect from an outsourcing partner. Covance will have to continue to manage this perception and proactively manage its preclinical operations.


    What Does the Deal Mean for thePreclinical Outsourcing Industry?


    If the Sanofi sites in France and the UK have preclinical capabilities, this would add capacity to a preclinical outsourcing industry that already has significant unused capacity due to low customer demand. The good news for the industry is that this would equate to lower capacity in the client community, but it appears that Covance would be the primary beneficiary of this reduction. The degree of exclusivity of the Covance-Sanofi deal will determine how much, if any, preclinical business is lost by Covance's competitors. On the other hand, the aforementioned client concerns that Covance has become too large could drive new business to small or mid-sized CROs. You can bet that Covance's competitors will jump at any opportunity to woo Covance clients, especially if any quality issues arise in the immediate future.


    Beyond the Covance-Sanofi deal, other changes in the preclinical outsourcing industry could impact the competitive landscape. It has been reported that LAB Research was recently put up for sale. Businesses are bought and sold all of the time, but such news can create uncertainty in the internal operations of a CRO and in the client community. Clients should make sure their due diligence is current and should maintain ongoing monitoring activities. Any detriment in the business of existing CROs will only benefit the competition. Along those lines, all CROs are potentially subject to operational changes due to the aforementioned stance by the FDA on contributor reports.


    The Covance-Sanofi partnership has obvious benefits for both parties. Covance will face operational challenges, just as it did with the Lilly deal, and although the preclinical outsourcing industry has experienced a long decrease in customer demand, Sanofi is a recent example of another pharmaceutical company that is diminishing its internal drug development capabilities. This trend is likely to continue as the pharmaceutical industry faces patent expirations on key drugs.


    In the end, the real significance of the Covance-Sanofi partnership may be the affirmation of a brighter future for the preclinical outsourcing industry.


    Steve Snyder is a consultant with more than 25 years of experience in preclinical toxicology as an outsourcing customer and provider. He can be contacted at info@outsource-support.com.

    Related Searches
    • preclinical cro
    • Development
    • Preclinical
    • CRO
    Suggested For You
    Frontage Laboratories Appoints Executive Director, Regional Head of Sales, West Frontage Laboratories Appoints Executive Director, Regional Head of Sales, West
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    Recro Gainesville Expands Mfg. Capabilities Recro Gainesville Expands Mfg. Capabilities
    Diverse Products And Technologies Delivered Diverse Products And Technologies Delivered
    PPD Expands Vaccine Development Lab PPD Expands Vaccine Development Lab
    UPM Celebrates 100-Years of Mfg. at Tennessee Site UPM Celebrates 100-Years of Mfg. at Tennessee Site
    Breaking New Ground: How Industry Collaboration is Transforming Clinical Research Breaking New Ground: How Industry Collaboration is Transforming Clinical Research
    Worldwide Clinical Trials Names EVP of Global BD Worldwide Clinical Trials Names EVP of Global BD
    Celerion Appoints CMO Celerion Appoints CMO
    Ancillare Appoints Asia-Pac VP Ancillare Appoints Asia-Pac VP
    Veeva Systems Expands Leadership Team Veeva Systems Expands Leadership Team
    12 Lilly 12 Lilly
    Lilly, Regen BioPharma in Drug Discovery Pact Lilly, Regen BioPharma in Drug Discovery Pact
    Lilly Licenses Halozyme’s ENHANZE platform Lilly Licenses Halozyme’s ENHANZE platform
    Lilly Halts Development of BIL Lilly Halts Development of BIL

    Related Content

    • Breaking News | Industry News | Promotions & Moves
      Frontage Laboratories Appoints Executive Director, Regional Head of Sales, West

      Frontage Laboratories Appoints Executive Director, Regional Head of Sales, West

      John Foster will be accountable for overseeing business development efforts in the western US.
      Charles Sternberg, Assistant Editor 04.29.21

    • Breaking News | Facilities | Industry News | Inspections
      Frontida BioPharm Launches Expansion Efforts

      Frontida BioPharm Launches Expansion Efforts

      Comes on heels of receiving FDA clearance
      05.26.17

    • Breaking News | Facilities | Industry News | Solid Dosage/Creams/Ointments | Solid Dosage/Semi-solids
      Recro Gainesville Expands Mfg. Capabilities

      Recro Gainesville Expands Mfg. Capabilities

      Installs new tableting equipment and grows development team
      05.24.17


    • Diverse Products And Technologies Delivered

      Diverse Products And Technologies Delivered

      For Avanir, Breath Powered Meets Pharma Tech's Breadth of Services

    • Bioanalytical Services | Biologics, Proteins, Vaccines | CRO News | Drug Development | Laboratory Testing
      PPD Expands Vaccine Development Lab

      PPD Expands Vaccine Development Lab

      Expands capacity for vaccine efficacy testing using techniques such as cell-based assays and immunochemistry
      05.19.17

      Trending
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Hanmi Fine Chemical Launches CDMO Business | Contract Pharma
      • CureVac, MyNEO Partner On Antigen Targets For MRNA-Cancer Vax Development | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • Insmed Appoints Drayton Wise As Chief Commercial Officer | Contract Pharma
      Breaking News
      • iECURE Enters Agreement with Center for Breakthrough Medicines
      • CPDC Enters Clinical Manufacturing Deal with CellBion
      • Olon to Build New R&D Center in Italy
      • Hanmi Fine Chemical Launches CDMO Business
      • DFE Pharma Opens India CoE for Fast-Track Formulation Services
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      Nippon Paint Automotive Americas Appoints Robert Angart CEO and President
      Sustainability, Economy are Focus of BCF’s Annual Conference
      Demand for Rhino Shield Increases
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—May 28
      New Breast Implant Surgery Guidelines to Enhance Patient Safety
      Rhythm Management Group Debuts RhythmSynergy Tech Platform
      Contract Pharma

      Latest Breaking News From Contract Pharma

      iECURE Enters Agreement with Center for Breakthrough Medicines
      CPDC Enters Clinical Manufacturing Deal with CellBion
      Olon to Build New R&D Center in Italy
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      K-Beauty Brand Siita Shares Plastic Decomposition Technology with the Beauty Industry
      Shellworks Raises $6.2 Million in Seed Funding
      Ulta Beauty Reports Record First Quarter 2022 Results
      Happi

      Latest Breaking News From Happi

      Global Skincare Treatment Devices Market Expected to Grow at Over 11.5% CAGR Rate Through 2028
      Technology Cuts Plastic Decomposition from 500 Years to Three Months
      Honeywell Addresses Critical Issues Such as Sustainability, Workforce Training and Digitalization
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Flint Group, New Inks from Siegwerk and Zeller+Gmelin Lead This Week’s News
      Orion to Finish Gas Black Expansion in Germany by Early 2023
      Richard Childress Racing Shows Off New Wraps for 2022 NASCAR Season
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      UPM Raflatac accelerates label growth with acquisition
      Labelexpo Asia 2022 postponed
      Teklynx software helps Top Clean Injection validate labels
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most-Read Stories This Week—May 28
      Toetal Solutions Raises $1.02 Million in New Financing
      ManaMed's ManaSport Wearable Ultrasound Earns FDA Nod
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: OPV’s Future, Graphene Flagship and Japan Display Top This Week’s Stories
      SEMI Foundation Receives $1.5 Million Grant to Bolster Michigan’s Semiconductor Talent Pipeline
      onsemi Recognized by Fortune 500 for Its Transformation Journey

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login